Members
 | First name: Melanie Last name: Bertine Function: Post-doc researcher Position: Clinical studies engineer Email: melanie.bertineaphp.fr |
Research interest
My main research interests are HIV-2 physiopathology and reservoir. Indeed, the laboratory is the virological coordinator of the cohort ANRS HIV-2 with over 1 000 patients included, the larger HIV-2 cohort in Northern countries. I develop several methods to determine HIV-2 reservoir and study the role of the defence cellular protein APOBEC3 and its control by the vif viral gene in HIV-2 physiopathology. I am also involved in studying HIV resistance using both Sanger and NGS technologies. I also participate to the management in the laboratory of the ANRS clinical trials conducted in our hospital.
Education
Degree
2015: Ph. D. in Infectiology and Microbiology, option Virology, University Paris Diderot
2008: Master Degree in Infectiology (Microbiology, Virology and Immunology), specialty Molecular and Medical Microbiology, University Paris Diderot
2006: Licence in Biochemistry and Molecular Biology, University Paris Diderot
2005: General university degree in Science and Technology, option life sciences, University Paris Diderot
2008: Master Degree in Infectiology (Microbiology, Virology and Immunology), specialty Molecular and Medical Microbiology, University Paris Diderot
2006: Licence in Biochemistry and Molecular Biology, University Paris Diderot
2005: General university degree in Science and Technology, option life sciences, University Paris Diderot
Academic positions
2011-present: Clinical Studies Engineer (ANRS funds), Laboratory of Virology, Hospital Bichat Claude Bernard, Paris
2010-2011: Clinical Studies Engineer, Laboratory of Microbiology, Hospital Bichat Claude Bernard, Paris
2010-2011: Clinical Studies Engineer, Laboratory of Microbiology, Hospital Bichat Claude Bernard, Paris
Research training (post doctoral)
2012-2015: « Characterization of APOBEC3F/3G-induced defective viruses in HIV-2 infection », Ph. D, Laboratory of Virology, UMR 1137 IAME INSERM, University Paris Diderot, Hospital Bichat Claude Bernard, Paris.
2010-2011: « Study of the emergence of resistance to methicillin in staphylococcal nasal flora in patients from general medicine treated with antibiotics », Laboratory of Microbiology, EA3964 University Paris Diderot, Hospital Bichat Claude Bernard, Paris.
2007-2008: « Development of real-time quantitative RT-PCR and application for the study of Bordetella isolates », Master Degree, Unit for the Prevention and Molecular Therapy of Human Diseases , URA 3012 CNRS, Pasteur Institute, Paris.
2007: « Study of the biodiversity of the carriage of Staphylococcus aureus in a population of Native Americans isolated in Guyana », Laboratory of Microbiology, EA3964, University Paris Diderot, Hospital Bichat Claude Bernard, Paris.
2010-2011: « Study of the emergence of resistance to methicillin in staphylococcal nasal flora in patients from general medicine treated with antibiotics », Laboratory of Microbiology, EA3964 University Paris Diderot, Hospital Bichat Claude Bernard, Paris.
2007-2008: « Development of real-time quantitative RT-PCR and application for the study of Bordetella isolates », Master Degree, Unit for the Prevention and Molecular Therapy of Human Diseases , URA 3012 CNRS, Pasteur Institute, Paris.
2007: « Study of the biodiversity of the carriage of Staphylococcus aureus in a population of Native Americans isolated in Guyana », Laboratory of Microbiology, EA3964, University Paris Diderot, Hospital Bichat Claude Bernard, Paris.
List of the main publications
Bertine M, Visseaux B, Storto A, Collin G, Matheron S, Descamps D, Charpentier C, ACH2C
HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
Journal of Acquired Immune Deficiency Syndromes (1999) 2016, 72, e9–e11.
Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ACH2C
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.
Charpentier C, Eholié S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoël V, Messou E, Minga A, Damond F, Plantier JC, Dabis F, Peytavin G, Brun-Vézinet F, Ekouevi DK, IWAC
Genotypic resistance profiles of HIV-2-treated patients in West Africa.
AIDS (London, England) 2014, 28, 1161–1169.
Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vézinet F, Plantier JC, Descamps D
In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
AIDS (London, England) 2013, 27, 2959-2961.
HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
Journal of Acquired Immune Deficiency Syndromes (1999) 2016, 72, e9–e11.
Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ACH2C
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.
Charpentier C, Eholié S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoël V, Messou E, Minga A, Damond F, Plantier JC, Dabis F, Peytavin G, Brun-Vézinet F, Ekouevi DK, IWAC
Genotypic resistance profiles of HIV-2-treated patients in West Africa.
AIDS (London, England) 2014, 28, 1161–1169.
Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vézinet F, Plantier JC, Descamps D
In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
AIDS (London, England) 2013, 27, 2959-2961.
Exhaustive list of publications
2022
Houhou-Fidouh N, Bucau M, Bertine M, Minh TNT, Picone O, Salakos E, Luton D
Preliminary results on transmission of SARS-CoV-2 antibodies to the fetus and serum neutralizing activity.
International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics 2022, 158, 476-478.
Bouzid D, Hadad O, Bertine M, Houhou-Fidouh N, Mirand A, Duval X, Bunel V, Borie R, Lucet JC, Descamps D, Visseaux B
Rhinoviruses: molecular diversity and clinical characteristics.
International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2022, 118, 144-149.
2021
Diallo MS, Samri A, Charpentier C, Bertine M, Cheynier R, Thiébaut R, Matheron S, Collin F, Braibant M, Candotti D, Brun-Vézinet F, Autran B, ACI2aACASG
A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected Nonprogressors.
AIDS research and human retroviruses 2021, 37, 214-223.
Visseaux B, Bertine M, Le Hingrat Q, Ferré V, Charpentier C, Collin F, Damond F, Matheron S, Hué S, Descamps D
HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution.
Virus Evolution 2021, 7, veab024.
Delaroche L, Bertine M, Oger P, Descamps D, Damond F, Genauzeau E, Meicler P, Le Hingrat Q, Lamazou F, Gschwind R, Ruppé E, Visseaux B
Evaluation of SARS-CoV-2 in semen, seminal plasma, and spermatozoa pellet of COVID-19 patients in the acute stage of infection.
PloS One 2021, 16, e0260187.
2020
Hingrat QL, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y, Duval X, Burdet C, Ichou H, Damond F, Bertine M, Benmalek N, Choquet C, Timsit JF, Ghosn J, Charpentier C, Descamps D, Houhou-Fidouh N, FCcmcCCsg, motFCcsg(ao, motCCsgPi, SC, CCCC, Casa, VL, BC, P, S, G
Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2020, S1198-743X(20)30721-7.
Wirden M, Feghoul L, Bertine M, Nere ML, Le Hingrat Q, Abdi B, Boutolleau D, Ferre VM, Jary A, Delaugerre C, Marcelin AG, Descamps D, Legoff J, Visseaux B, Chaix ML
Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2020, 130, 104573.
Bleibtreu A, Bertine M, Bertin C, Houhou-Fidouh N, Visseaux B
Focus on Middle East respiratory syndrome coronavirus (MERS-CoV).
Médecine et Maladies Infectieuses 2020, 50, 243-251.
Le Hingrat Q, Visseaux B, Bertine M, Chauveau L, Schwartz O, Collin F, Damond F, Matheron S, Descamps D, Charpentier C
Genetic Variability of Long Terminal Repeat Region between HIV-2 Groups Impacts Transcriptional Activity.
Journal of Virology 2020, 94,
2019
Le Hingrat Q, Collin G, Lê M, Peytavin G, Visseaux B, Bertine M, Tubiana R, Karmochkine M, Valin N, Collin F, Lemaignen A, Bernard L, Damond F, Matheron S, Descamps D, Charpentier C, FNAfRoAaVH(CH2C
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019, 69, 657-667.
Samri A, Charpentier C, Diallo MS, Bertine M, Even S, Morin V, Oudin A, Parizot C, Collin G, Hosmalin A, Cheynier R, Thiébaut R, Matheron S, Collin F, Zoorob R, Brun-Vézinet F, Autran B, ACI2SG
Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection.
PLoS pathogens 2019, 15, e1007758.
2018
Le Hingrat Q, Perrier M, Collin G, Drumard S, Storto A, Bertine M, Larrouy L, Matheron S, Damond F, Charpentier C, Descamps D, Visseaux B
Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads.
Journal of Virological Methods 2018, 257, 12-15.
Storto A, Visseaux B, Bertine M, Le Hingrat Q, Collin G, Damond F, Khuong MA, Blum L, Tubiana R, Karmochkine M, Cazanave C, Matheron S, Descamps D, Charpentier C, AH2CC
Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2018
Perrier M, Désiré N, Storto A, Todesco E, Rodriguez C, Bertine M, Le Hingrat Q, Visseaux B, Calvez V, Descamps D, Marcelin AG, Charpentier C
Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants.
PloS One 2018, 13, e0198334.
2017
Alessandri-Gradt E, Collin G, Tourneroche A, Bertine M, Leoz M, Charpentier C, Unal G, Descamps D, Plantier JC
HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2431-2437.
Perrier M, Bertine M, Le Hingrat Q, Joly V, Visseaux B, Collin G, Landman R, Yazdanpanah Y, Descamps D, Charpentier C
Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2954-2955.
Todesco E, Charpentier C, Bertine M, Wirden M, Storto A, Desire N, Grude M, Nguyen T, Sayon S, Yazdanpanah Y, Katlama C, Descamps D, Calvez V, Marcelin AG
Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations.
HIV medicine 2017, 18, 696-700.
Bertine M, Gueudin M, Mélard A, Damond F, Descamps D, Matheron S, Collin F, Rouzioux C, Plantier JC, Avettand-Fenoel V
New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification.
Journal of Clinical Microbiology 2017, 55, 2850-2857.
2016
Bertine M, Visseaux B, Storto A, Collin G, Matheron S, Descamps D, Charpentier C, ACH2C
HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
Journal of Acquired Immune Deficiency Syndromes (1999) 2016, 72, e9–e11.
2015
Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ACH2C
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.
Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D, ACH2C
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
PloS One 2015, 10, e0134904.
2014
Alioua MA, Labid A, Amoura K, Bertine M, Gacemi-Kirane D, Dekhil M
Emergence of the European ST80 clone of community-associated methicillin-resistant Staphylococcus aureus as a cause of healthcare-associated infections in Eastern Algeria.
Médecine Et Maladies Infectieuses 2014, 44, 180–183.
Charpentier C, Eholié S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoël V, Messou E, Minga A, Damond F, Plantier JC, Dabis F, Peytavin G, Brun-Vézinet F, Ekouevi DK, IWAC
Genotypic resistance profiles of HIV-2-treated patients in West Africa.
AIDS (London, England) 2014, 28, 1161–1169.
2013
Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vézinet F, Plantier JC, Descamps D
In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
AIDS (London, England) 2013, 27, 2959-2961.
